Encompass Wealth Advisors LLC recently acquired 1,063 shares of The Sherwin-Williams Company (NYSE:SHW), adding to its already impressive portfolio of specialty chemicals. The disclosure was made in the company’s most recent filings with the Securities and Exchange Commission (SEC), providing transparency to all stakeholders.
The decision to acquire these shares stems from impressive numbers in Sherwin-Williams’ recent earnings report. The report, released Thursday, Jan. 26, put his net profit margin at 9.12% and his return on equity at 90.04%. That’s after he posted his earnings per share (EPS) of $1.89 for the quarter, up $0.05 from analyst consensus forecasts.
Additionally, Sherwin-Williams posted revenue of $5.23 billion during the quarter, supported by 9.8% year-over-year growth, according to the report. These results have led sell-side analysts to expect Sherwin-Williams to hit her EPS of 8.5 this year.
Despite this positive trajectory, several deals recently revealed by the SEC involving Sherwin-Williams executives are also worth noting. For example, SVP Bryan J Young sold 2,750 shares in February for about $607,090.00. and the average price per share was $220.76. However, he still owns more than 7,000 of his shares in the company.
It’s also worth noting that CEO John G Morikis bought 2,207 shares at the end of January at an average price of $226.70 per share in a deal of over $500,000.
Finally, Sherwin-Williams continues to attract investor interest, especially given its impressive performance in this difficult economic season, as would be expected from publicly traded companies reporting strong results.
Investors interested in tracking The Sherwin-Williams Company’s performance would be wise to monitor future financial reporting releases and management decisions. Meanwhile, Encompass Wealth Advisors LLC will continue to evaluate opportunities in the Specialty Chemicals segment, as well as its acquisition of Sherwin-Williams shares, to capitalize on investments that deliver impressive returns.
Institutional investors and hedge funds flock to Sherwin-Williams for long-term gains
The Sherwin-Williams Company has attracted the attention of institutional investors and hedge funds in recent months, with shares in the company being bought and sold. For example, Roundview Capital LLC increased its stake in a specialty chemicals company by 8.1% in the first quarter, while Cibc World Market Inc. increased its stake by 189.1% over the same period. Sei Investments Co., Prudential PLC and Cetera Investment Advisers also joined the position.
Currently trading at $225.65 per share, Sherwin-Williams has a debt-to-equity ratio of 3.09 and a market capitalization of $58.23 billion. The company has a 50-day simple moving average of $223.01 and a 200-day simple moving average of $229.62.
CEO John G. Mollikis recently purchased more than 2,000 shares of the company at an average price of $226.70, while senior vice president Brian J. Young sold 2,750 shares at an average price of $220.76 on February 23.
On March 10, Sherwin-Williams paid out its quarterly dividend to investors recorded as holding shares on February 27. This is up from the last quarterly dividend to total $0.605 per share for the year. This equates to a yield of approximately *1%.
Several research analysts issued reports on the stock with lower target prices for Sherwin-Williams based on recent earnings reports. Currently, the overall consensus rating is “moderate buy”.
With more than three-quarters (76.03%) of its outstanding shares held by hedge funds and institutional investors such as healthcare providers and universities through its investment arm and endowments, Sherwin-Williams is a long-term investor. It seems like an attractive proposition for those looking for good profits. from investment.